Decera Clinical Education Oncology Podcast

In this podcast episode, Christine M. Bestvina, MD, and Joshua E. Reuss, MD, discuss the current and emerging role of TROP2-directed ADCs in NSCLC, including: Current clinical use of Dato-DXd in previously treated EGFR -mutated NSCLC, including evidence from TROPION-Lung01 and TROPION-Lung05 and considerations for treatment sequencing Emerging efficacy data for investigational TROP2 ADCs, including sacituzumab tirumotecan, and the potential role of these agents in earlier lines of therapy Ongoing clinical trials evaluating TROP2 ADCs alone and in combination with immunotherapy, chemotherapy, or EGFR-targeted therapies, including TROPION-Lung07, TROPION-Lung08, TROPION-Lung14, TROPION-Lung15, and AVANZAR Biomarker-guided patient selection, including the potential of the TROP2 QCS-NMR biomarker to identify patients most likely to benefit from Dato-DXd Safety and supportive care considerations, including prevention and management of stomatitis, ocular toxicities, and interstitial lung disease/pneumonitis Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenters: Christine M. Bestvina, MD Associate Professor of Medicine Section of Hematology/Oncology Division of Medicine University of Chicago Medicine Chicago, Illinois Joshua E. Reuss, MD Thoracic Medical Oncologist Director of Thoracic Clinical Research Associate Professor of Medicine Georgetown Lombardi Comprehensive Cancer Center Washington, DC Link to full program: https://bit.ly/4iumiap Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Jesus G. Berdeja, MD, and Ajai Chari, MD, discuss evolving therapy in newly diagnosed multiple myeloma, including: Selecting quadruplet therapy Optimal use of bortezomib The role of autologous stem cell transplantation in the quadruplet era Use of MRD status to inform treatment decisions Maintenance strategies Presenters : Jesus G. Berdeja, MD Director of Myeloma Research Greco-Hainsworth Centers for Research Partner Tennessee Oncology Nashville, Tennessee Ajai Chari, MD Professor of Clinical Medicine Director of Multiple Myeloma Program UCSF Helen Diller Family Comprehensive Cancer Center University of California, San Francisco (UCSF) Medical Center San Francisco, California Content based on an online CME program supported by an educational grant from GSK. Link to full program: https://bit.ly/4yTeLZD Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Neeraj Agarwal, MD, FASCO, and Emmanuel S. Antonarakis, MD, discuss the evolving role of PARP inhibitors in metastatic prostate cancer, emphasizing early molecular testing to identify appropriate patients for PARP-directed therapy and proactive adverse event management to support treatment continuation, including: HRR alterations and the mechanism of action of PARP inhibitors Germline and somatic genomic testing and practical considerations for tissue and ctDNA testing PARP inhibitor monotherapy and combination strategies, including data from AMPLITUDE and TALAPRO-3 Treatment selection across metastatic prostate cancer settings based on HRR alterations PARP inhibitor toxicity management, with emphasis on anemia, gastrointestinal effects, monitoring, and dose modification Presenters: Neeraj Agarwal, MD, FASCO Medical Oncologist, Dana-Farber Cancer Institute Co-Director, Prostate Cancer Program, Harvard Cancer Consortium The Lank Center for Genitourinary Oncology Boston, Massachusetts Emmanuel S. Antonarakis, MD Clark Endowed Professor of Medicine Director of GU Oncology, Associate Director of Translation Division of Hematology, Oncology and Transplantation University of Minnesota, Masonic Cancer Center Minneapolis, Minnesota Link to full program: https://bit.ly/4dtT35U Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Listen to Jesus G. Berdeja, MD, and Ajai Chari, MD, as they discuss sequencing of antibody–drug conjugates (ADCs), bispecific antibodies, CAR T-cell therapy, and other novel treatment modalities for patients with relapsed/refractory multiple myeloma. Presenters: Jesus G. Berdeja, MD Director of Myeloma Research Greco-Hainsworth Centers for Research Partner Tennessee Oncology Nashville, Tennessee Ajai Chari, MD Professor of Clinical Medicine Director of Multiple Myeloma Program UCSF Helen Diller Family Comprehensive Cancer Center University of California, San Francisco (UCSF) Medical Center San Francisco, California Content based on an online CME program supported by an educational grant from GSK. Link to full program: https://bit.ly/3TZSmuf Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Hope S. Rugo, MD, FASCO, and Nerea Lopetegui-Lia, MD, discuss practice-informing data presented at ASCO 2026 for patients with metastatic breast cancer, including: Findings from SERENA-6 on ctDNA-guided treatment switching for emergent ESR1 mutations before radiographic progression, including updated PFS2 and downstream treatment outcomes Emerging precision strategies in HR-positive/HER2-negative advanced breast cancer from ELEVATE and PIKALO-1, including elacestrant plus capivasertib and mutant-selective PI3Kα inhibition with tersolisib First-line TROP2-directed ADC data from ASCENT-04, ASCENT-03, and TROPION-Breast02, with discussion of PFS2, subsequent therapy, immunotherapy eligibility, and treatment sequencing Presenters: Hope S. Rugo, MD, FASCO Director, Women’s Cancer Program Division Chief, Breast Medical Oncology Professor, Department of Medical Oncology & Therapeutics Research City of Hope Comprehensive Cancer Center Professor Emeritus and Emeritus Winterhof Family Distinguished Professor of Breast Oncology University of California, San Francisco San Francisco, California Nerea Lopetegui-Lia, MD Assistant Professor Division of Medical Oncology, Breast Section Department of Internal Medicine The Ohio State University Columbus, Ohio Get access to all of our new podcasts by subscribing to the Decera Clinical Education [Oncology] Podcast on Apple Podcasts, YouTube Music, or Spotify. Link to full program: https://bit.ly/4x4u5AT Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Charles Rudin, MD, PhD, and Mark A. Socinski, MD, discuss current gaps and clinical needs for patients with relapsed ES-SCLC, and the evolving role of B7-H3–directed antibody–drug conjugates in the management of patients with ES-SCLC, including: Clinical needs for relapsed ES-SCLC Scientific rationale for targeting B7-H3 and other tumor-associated antigens in SCLC ADCs, T-cell engagers, chemotherapy-based approaches, maintenance strategies, and ongoing clinical trials for ES-SCLC Recent efficacy and safety data for B7-H3–directed ADCs in ES-SCLC, including I-DXd Personalization of care of patients with SCLC, including patient-specific factors influencing treatment Case discussion of a patient with ES-SCLC requiring optimal next best treatment Importance of enrolling patients in ongoing trials of investigational agents for patients with ES-SCLC Presenters: Charles Rudin, MD, PhD Cancer Center Director Memorial Sloan Kettering Cancer Center New York, New York Mark A. Socinski, MD Executive Medical Director AdventHealth Cancer Institute Orlando, Florida Link to full program: https://bit.ly/3UBEeYz Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, BJ Rimel, MD, and Elizabeth Lee, MD, discuss the scientific rationale for targeting CDH6 in ovarian cancer and the emerging role of CDH6-directed antibody–drug conjugates (ADCs) in platinum-resistant disease, including: CDH6 biology, expression patterns, and its potential as a therapeutic target in ovarian cancer Early-phase efficacy data with investigational CDH6-directed ADCs, including raludotatug deruxtecan (R-DXd) and CUSP06, and an ongoing phase III trial of R-DXd Safety considerations with CDH6-directed ADCs, including cytopenias, gastrointestinal toxicities, fatigue, and interstitial lung disease/pneumonitis Considerations for sequencing ADCs, including the potential impact of target expression, payload class, and mechanisms of resistance Presenters: BJ Rimel, MD Division Chief, Gynecologic Oncology Professor, Department of OB/GYN University of Washington Clinical Director of Gynecologic Oncology Fred Hutchinson Cancer Center Seattle, Washington Elizabeth Lee, MD Division of Gynecologic Oncology Center for Cancer Therapeutic Innovation Department of Medical Oncology Dana-Farber Cancer Institute Boston, Massachusetts Link to full program: https://bit.ly/3SqCAZ6 Get access to all of our new podcasts by subscribing to the Decera Clinical Education Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Hope S. Rugo, MD, FASCO, and Nerea Lopetegui-Lia, MD, discuss practice-informing data presented at ASCO 2026 for patients with early-stage hormone receptor (HR)–positive/HER2-negative breast cancer, including: Findings from the OPTIMA trial evaluating Prosigna gene expression testing to guide adjuvant chemotherapy decisions in patients with high-risk HR-positive/HER2-negative early breast cancer The importance of ovarian function suppression plus endocrine therapy when considering chemotherapy-sparing strategies in premenopausal patients Results from the NATALEE PAM50 biomarker analysis, showing ribociclib benefit across intrinsic subtypes with no significant treatment-by-subtype interaction Presenters: Hope S. Rugo, MD, FASCO Director, Women’s Cancer Program Division Chief, Breast Medical Oncology Professor, Department of Medical Oncology & Therapeutics Research City of Hope Comprehensive Cancer Center Professor Emeritus and Emeritus Winterhof Family Distinguished Professor of Breast Oncology University of California, San Francisco San Francisco, California Nerea Lopetegui-Lia, MD Assistant Professor Division of Medical Oncology, Breast Section Department of Internal Medicine The Ohio State University Columbus, Ohio Get access to all of our new podcasts by subscribing to the Decera Clinical Education [Oncology] Podcast on Apple Podcasts, YouTube Music, or Spotify. Link to full program: https://bit.ly/4x4u5AT Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Treatment options for patients with lymphoma are rapidly evolving. In this podcast episode, Alex F. Herrera, MD, and Marc Hoffmann, MD, discuss cereblon E3 ligase modulators (CELMoDs) as potential treatment options for patients with aggressive diffuse large B-cell lymphoma and follicular lymphoma, with a focus on golcadomide, an investigational, oral, first-in-class CELMoD therapy. Topic areas covered include: Biologic and clinical rationale for the use of CELMoD therapy in lymphoma patients Emerging clinical trial data on golcadomide alone and in combination with other regimens Real-world expectations for incorporating CELMoD-based therapies into community lymphoma care settings such as efficacy, patient selection, and toxicity management strategies Presenters: Alex F. Herrera, MD Chief, Division of Lymphoma Professor, Department of Hematology and Hematopoietic Cell Transplantation Director, Toni Stephenson Lymphoma Center City of Hope Duarte, California Marc Hoffmann, MD Director, Lymphoma Program Medical Director, Lean and Quality Improvement Associate Professor Division of Hematologic Malignancies and Cellular Therapeutics University of Kansas Cancer Center Kansas City, Kansas Content based on an online CME program supported by an educational grant from Bristol Myers Squibb. Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Link to CME: Claim Credit Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Jesus G. Berdeja, MD, and Ajai Chari, MD, discuss health disparities and equitable care strategies in multiple myeloma, including: Treatment for underserved populations Navigating REMS for novel therapeutics Clinical trial design and enrolment Presenters: Jesus G. Berdeja, MD Director of Myeloma Research Greco-Hainsworth Centers for Research Partner Tennessee Oncology Nashville, Tennessee Ajai Chari, MD Professor of Clinical Medicine Director of Multiple Myeloma Program UCSF Helen Diller Family Comprehensive Cancer Center University of California, San Francisco (UCSF) Medical Center San Francisco, California Content based on an online CME program supported by an educational grant from GSK. Link to full program: https://bit.ly/3TZSmuf Get access to all of our new podcasts by subscribing tothe Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Meletios-Athanasios (Thanos) C. Dimopoulos, MD, and María-Victoria Mateos, MD, PhD, as they discuss the use of CELMoD agents to manage multiple myeloma, including: The recent FDA approval of iberdomide Mechanism of action and differentiation from IMiDs Current data and potential treatment settings Presenters: Meletios-Athanasios (Thanos) C. Dimopoulos, MD Professor and Chairman Plasma Cell Dyscrasias Unit Section of Hematology and Medical Oncology Department of Clinical Therapeutics School of Medicine National and Kapodistrian University of Athens Alexandra Hospital Athens, Greece María-Victoria Mateos, MD, PhD Myeloma Unit, Director Professor of Medicine University Hospital of Salamanca Salamanca, Spain Content based on an online CME program supported by an educational grant from Bristol Myers Squibb. Link to full program: https://bit.ly/4xgnHri Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Danielle Roman, PharmD, BCOP, and Jordan Hill, PharmD, BCOP, discuss optimal care for patients with HR-positive/HER2-negative breast cancer receiving newer oral targeted therapies. Their conversation addresses treatment selection across early-stage and metastatic disease, biomarker-informed decision-making, adverse event management, and practical strategies to help patients remain on therapy. Key topics include: Selecting and sequencing oral targeted therapies, including CDK4/6 inhibitors, PARP inhibitors, PI3K/AKT pathway inhibitors, and oral SERDs Identifying patients with high-risk early breast cancer and applying evidence from trials such as monarchE, NATALEE, and OlympiA Using biomarkers such as BRCA1/2, PIK3CA, AKT1, PTEN, and ESR1 to guide therapy in metastatic disease Monitoring and managing treatment-related adverse events, including neutropenia, diarrhea, hepatotoxicity, QTc prolongation, hyperglycemia, rash, stomatitis, anemia, nausea, and fatigue Using dose modification, supportive care, patient education, and proactive follow-up to improve adherence and persistence with oral therapy Incorporating oncology pharmacists and the multidisciplinary care team into ongoing treatment monitoring and patient support Presenters Danielle Roman, PharmD, BCOP Manager, Oncology Clinical Pharmacy Services Oncology Clinical Pharmacy Specialist Allegheny Health Network Pittsburgh, Pennsylvania Jordan Hill, PharmD, BCOP Clinical Pharmacy Specialist, Breast Oncology West Virginia University Cancer Institute Morgantown, West Virginia Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Access the full educational program: Link to full program: https://bit.ly/4gvZerW And be sure to try our Interactive Decision Support Tools for Early Breast Cancer and Selecting AKT or PI3K Inhibitors for Patients With Metastatic Breast Cancer. By answering just a few quick questions, you can see what 5 experts would recommend for specific patient scenarios. Early Breast Cancer: https://bit.ly/4gtUiUq AKT or PI3K Inhibitors in MBC: https://bit.ly/4qcyBvk Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Tenosynovial giant cell tumor (TGCT) is a rare, locally aggressive disease that can cause chronic pain, joint dysfunction, reduced mobility, and significant impacts on quality of life, particularly in patients with diffuse disease. In this expert discussion, Dr William Tap and Dr Emanuela Palmerini explore the evolving management of TGCT, including the biologic role of the CSF1/CSF1R pathway, challenges in diagnosis and disease monitoring, and the importance of multidisciplinary, patient-centered care. They also discuss the growing role of CSF1R-targeted therapies, treatment selection, toxicity management, drug holidays, and practical approaches to optimizing long-term outcomes for patients living with TGCT. Topics Covered Understanding localized vs diffuse TGCT Biology of the CSF1/CSF1R pathway Diagnostic approaches and the role of MRI and biopsy Multidisciplinary care and shared decision-making Impact of TGCT on function, mobility, and quality of life Current and emerging CSF1R-targeted therapies Pexidartinib and vimseltinib: clinical considerations and toxicity management Response assessment beyond imaging Drug holidays, retreatment strategies, and long-term follow-up Future directions in TGCT research and treatment Faculty William Tap, MD Emanuela Palmerini, MD, PhD Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, James A. Davis, PharmD, BCOP, and Kelley L. Julian, PharmD, BCOP, discuss evidence-based strategies for managing smoldering and newly diagnosed multiple myeloma, including: Risk stratification and treatment selection for smoldering multiple myeloma Anti-CD38–based regimens for transplant-eligible and transplant-ineligible patients Clinical evidence supporting triplet and quadruplet therapies MRD assessment and response-adapted treatment strategies Frailty, transplant eligibility, and individualized treatment selection Subcutaneous anti-CD38 administration and premedication requirements Pharmacist-led supportive care, toxicity management, dose modification, and patient counseling Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenters: James A. Davis, PharmD, BCOP Clinical Pharmacy Specialist, Myeloma/Lymphoma The Medical University of South Carolina, Hollings Cancer Center Affiliate Assistant Professor MUSC College of Pharmacy Charleston, South Carolina Kelley L. Julian, PharmD, BCOP Hematology/BMT Pharmacy Supervisor PGY2 Oncology Pharmacy Residency Program Director Huntsman Cancer Institute, University of Utah Salt Lake City, Utah Link to full program: https://bit.ly/4qaRb7n Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Gilles Salles, MD, PhD, and Pier Luigi Zinzani, MD, PhD, discuss the role of new and emerging targeted therapies in the management of patients with DLBCL, including: Overview of Unmet Needs With Current Standard of Care in DLBCL Expanding Role of Novel Agents in DLBCL Access to Targeted Therapies and Clinical Trials in Non-Academic DLBCL Practice Key Ongoing Trials of new and novel agents in DLBCL Key Presentations/Results at EHA 2026 in DLBCL Presenters: Gilles Salles, MD, PhD Service Chief, Lymphoma Service Steven Greenberg Chair Memorial Sloan Kettering Cancer Center Weill Cornell University New York, New York Pier Luigi Zinzani, MD, PhD Professor of Hematology Alma Mater Studiorum-University of Bologna Head, “Seràgnoli” Institute of Hematology IRCCS Azienda Ospedaliero-Universitaria di Bologna Department of Medical and Surgical Sciences Bologna University School of Medicine Bologna, Italy Link to full program: https://bit.ly/4gmyoS7 Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

New data and broad indications for trastuzumab deruxtecan are changing the paradigm for HER2-positive early breast cancer. Listen to Shanu Modi, MD, and Sara A. Hurvitz, MD, FACP, discuss how they are incorporating these changes into clinical practice in the neoadjuvant, adjuvant, and possibly metastatic settings. Presenters: Sara A. Hurvitz, MD, FACP Professor of Medicine Smith Family Endowed Chair in Women’s Health Senior Vice President, Clinical Research Division Fred Hutch Cancer Center Head, Division of Hematology/Oncology, Department of Medicine University of Washington School of Medicine Seattle, Washington Shanu Modi, MD Section Head, HER2 Breast Program Professor and Attending Member Breast Medicine Service, Department of Medicine Memorial Sloan Kettering Cancer Center Weill Cornell Medical College New York, New York Link to full program: https://bit.ly/4z1Xb6a Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Listen in to learn from Sagar Lonial, MD, and Mohamad Mohty MD, PhD, about the advantages and future implications of the next-generation protein degradation modulator based therapy and find out how to integrate their use into your practice. Presenters: Sagar Lonial, MD, FACP, FASCO Chair and Professor Department of Hematology and Medical Oncology Anne and Bernard Gray Family Chair in Cancer Chief Medical Officer Winship Cancer Institute Emory University School of Medicine Atlanta, Georgia Mohamad Mohty, MD, PhD Sorbonne University Paris, France Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Visit the program page for more content associated with this discussion. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Natalie S. Callander, MD, and Tom Martin, MD, discuss the optimal approaches for the determination of whether a patient with high-risk SMM requires treatment or observation, including: Contemporary Risk Stratification Interpreting Evidence for Early Intervention Treatment vs Observation: Patient Selection Treatment Selection and Sequencing Considerations Safety, Monitoring, and Supportive Care Implementation in Practice Shared Decision-making and Patient Communication Emerging Therapies and Clinical Trials Presenters: Natalie S. Callander, MD Professor of Medicine Director, Myeloma Clinical and Cellular Therapy Program University of Wisconsin Carbone Cancer Center Madison, Wisconsin Tom Martin, MD Professor of Medicine Associate Chief, Hematology/Oncology UCSF Medical Center San Francisco, California Link to full program: https://bit.ly/4wqpYzU Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Listen in to learn from Thomas Bachelot, MD, PhD, and Mafalda Oliveira, MD, PhD, about recent advances and the integration of anti-TROP2 antibody-drug conjugates (ADCs) into the management of patients with triple-negative breast cancer, including as first-line therapy for those who are not eligible for immunotherapy. Experts will cover: The evolving role of TROP2-directed antibody-drug conjugates (ADCs), including sacituzumab govitecan and datopotamab deruxtecan, in addressing unmet needs in the frontline treatment of TNBC. Treatment sequencing, reimbursement barriers to recent approvals, and toxicity-informed treatment selection considerations. How to monitor and manage ocular and pulmonary toxicities and care-team readiness for implementing ADC-based therapy in routine practice. Presenters: Thomas Bachelot, MD, PhD Medical Oncology Department of Oncology Léon Bérard Center Lyon, France Mafalda Oliveira, MD, PhD Senior Consultant Medical Oncology Department Vall d’Hebron University Hospital Senior Clinical Investigator Breast Cancer Group Vall d’Hebron Institute of Oncology (VHIO) Vall d’Hebron Barcelona Hospital Campus Barcelona, Spain Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Visit the program page for more content associated with this discussion. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Dr Sara Ann Scott and Dr Syeda Saba Kareem discuss toxicities and the safe management of bispecific antibodies used in the treatment of RRMM to improve outcomes for patients, including: The incidence of cytokine release syndrome (CRS), along with the grading system, treatment strategies, and the role of tocilizumab Neurologic toxicities like the clinical manifestation of ICANS and the ICE scoring system used to help assign grading and appropriate treatment with dexamethasone, levetiracetam, and/or high-dose methylprednisolone Infection susceptibilities associated with BCMA-targeted bispecific antibodies and how this varies for GPRC5D-directed targets throughout therapy How to set up and maintain a REMS program Get access to all of our new podcasts by subscribing to the Decera Clinical Education Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenters: Syeda Saba Kareem, PharmD, BCOP Clinical Pharmacy Supervisor Malignant Hematology Moffitt Cancer Center Tampa, Florida Sara A. Scott, PharmD, BCOP Clinical Pharmacy Specialist, Multiple Myeloma Emory Winship Cancer Institute Atlanta, Georgia Link to full program: https://bit.ly/3RUyrMx Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.